PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
about
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior.Implications of the tumor immune microenvironment for staging and therapeutics.A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.New developments in the management of head and neck cancer – impact of pembrolizumab.The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitorsImmune-checkpoint inhibitors for combating T-cell dysfunction in cancerDurvalumab in NSCLC: latest evidence and clinical potentialPrognostic impact of the tumor immune microenvironment in synovial sarcomaClinicopathological analysis of PD-L2 expression in colorectal cancer
P2860
Q38642853-6BFD3042-60EE-4169-B934-DE194071076AQ38833182-E8202D38-6C5C-414C-9DEC-4298E1C0C615Q47105057-BA9B4C0B-DDCE-47FF-B413-1C88EADE5C1FQ47115697-3B0197E2-AC2C-47E6-9288-9E5A545CBA8CQ47162071-8CB4FF72-B744-40CA-8823-1BAFBD094CF7Q47165377-962EFBBE-21B0-4500-AF5F-178FE5A928CEQ47181092-CA866FDB-DF98-42BB-ABC4-A16CCBD9492FQ47592007-47E7455C-05C4-4CEC-9EFE-A3F5700D7452Q50027076-7FF2C85B-1093-403E-9051-2CDFEB3B7E9FQ50077322-0466A7B4-9C5B-4AD8-847D-0D724DE3570EQ50336126-BC69D5C1-3FE4-49E4-A845-5CC9DEFD260BQ50545414-6C5F1534-8A56-46FD-9244-9E6788F7593FQ55113686-3C60D279-6ED1-4152-8FA8-A9D1EEDF3FCFQ55243180-F071C11E-56A2-4762-80CF-3B85E2C32AE6Q56888862-157850A5-DA7E-4B9A-9D12-343924EBA8CBQ56890243-1E723E19-9594-4076-8A39-434F28644F9FQ57483931-5C6A4474-26DA-4D1F-B8B6-E0C178E8F3D8Q57816055-CF4D6EEF-9415-4B79-B5AF-21C3B007A099Q58735481-6743A0F1-E327-473D-BB66-6D78227E9686Q59135196-D11D246A-95A4-46FF-B221-7DFAA408FB44
P2860
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
@en
type
label
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
@en
prefLabel
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
@en
P2093
P1476
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
@en
P2093
Christina Moon
Christopher Gibson
Erin Murphy
Jared Lunceford
Jennifer H Yearley
Joanne E Tomassini
Jonathan Cheng
Jonathan Juco
Laura Q M Chow
Masahisa Handa
P304
P356
10.1158/1078-0432.CCR-16-1761
P407
P577
2017-06-01T00:00:00Z